New study shows focal therapy effectively treats prostate cancer, keeping patients cancer free ten years after treatment
New study shows focal therapy effectively treats prostate cancer, keeping patients cancer free ten years…
Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer
Drugmaker Astrazeneca said on Monday that its cancer drug Truqap, used with abiraterone and prednisone, has been approved…